跳至主要内容
临床试验/NCT01062698
NCT01062698终止不适用

The Contribution of Intra-arterial Thrombectomy in Acute Ischemic Stroke in Patients Treated With Intravenous Thrombolysis

Central Hospital, Nancy, France1 个研究点 分布在 1 个国家目标入组 412 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
发起方
入组人数
412
试验地点
1
主要终点
Modified Rankin Score (mRs )

研究概览

简要总结

THRACE is a controled, multicenter and randomized trial.

The primary objective of this study is to determine whether a combined approach intravenous thrombolysis (IV) + Mechanical thrombectomy is superior to the reference treatment with IV thrombolysis alone, in the 3 hours of onset of symptoms in patients with occlusion of proximal cerebral arteries and with a neurological impairment accident (National Institutes of Health Stroke Scale [NIHSS] ≥ 10).

The second objective is to determine the cost-effectiveness of this procedure compared to the standard (IV thrombolysis). The assumption is that the combined approach, by improving the clinical outcome and speed recovery, allows for lower overall costs to the IV thrombolysis in 3 months and less than or at worst neutral to 1 year.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 10<=NIHSS Score=<25
  • Symptoms onset less than 4 hours
  • Occlusion of the intracranial carotid, the middle cerebral artery (M1) or the upper third of the basilar

排除标准

  • Contraindications for intravenous thrombolysis
  • Occlusion or stenosis of the pre-occlusive cervical internal carotid artery ipsilateral to the lesion
  • Any cause local prohibiting femoral catheterization

研究组 & 干预措施

IV thrombolysis + thrombectomy

Active Comparator

干预措施: Alteplase (rt-PA)/Actilyse (Drug)

IV thrombolysis + thrombectomy

Active Comparator

干预措施: Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE) (Procedure)

IV thrombolysis

Active Comparator

干预措施: Alteplase (rt-PA)/Actilyse (Drug)

结局指标

主要结局

Modified Rankin Score (mRs )

时间窗: 3 months after treatment

次要结局

  • Quality of Life (Euroqol EQ-5D)(3 months after treatment)
  • Barthel Score(3 months after treatment)

研究者

发起方
Central Hospital, Nancy, France
申办方类型
Other
责任方
Principal Investigator
主要研究者

Directeur de la Recherche et de l'Innovation

Professor Serge BRACARD

Central Hospital, Nancy, France

研究点 (1)

Loading locations...

相似试验

Trial and Cost Effectiveness Evaluation of... | 临床试验